1-3 of 3
Yves Reguerre, MD
Close
Sort by
Journal Articles

Imatinib in Children with Chronic Myeloid Leukemia in Chronic Phase: Long-Term Results of the French National Phase IV Trial

Hélène Deutsch, MD, Andre Baruchel, Joelle Guilhot, PhD, Arnaud Petit, MD PhD, Thierry Leblanc, MD, Yves Bertrand, MD, Brigitte Nelken, MD, Catherine Paillard, MD PhD, Cécile Verite, MD, Yves Réguerre, MD, Francoise Mechinaud, MD FRACP, Francois Guilhot, MD, Frederic Millot
Journal: Blood
Blood (2019) 134 (Supplement_1): 4147.
https://doi.org/10.1182/blood-2019-124060
Published: 2019
Journal Articles

Molecular Responses At 3 Months Are Associated With a Better Subsequent Molecular response and Outcome In Children and Adolescents With CML In Chronic Phase: Results Of a Retrospective Analysis From The French Glivec Phase 4 Study

Frédéric Millot, Joelle Guilhot, PhD, André Baruchel, MD, Arnaud Petit, MD, Thierry Leblanc, MD, Yves Bertrand, Françoise Mazingue, Patrick Lutz, Cécile Vérité, MD, Christian Berthou, MD, Claire Galambrun, MD, Nicolas Sirvent, Karima Yacouben, Pascal Chastagner, Virginie Gandemer, MD, PhD, Yves Reguerre, MD, Gérard Couillaud, MD, Jean-Michel Cayuela
Journal: Blood
Blood (2013) 122 (21): 2730.
https://doi.org/10.1182/blood.V122.21.2730.2730
Published: 2013
Journal Articles

Imatinib Is Efficient but Has a Negative Impact On Growth in Children with Previously Untreated chronic Myelogenous Leukaemia (CML) in Early Chronic Phase (CP): Results of the French National Phase IV Trial.

Frédéric Millot, MD, Andre Baruchel, MD, Joelle Guilhot, BS, Arnaud Petit, MD, Thierry Leblanc, MD, Yves Bertrand, MD, Françoise Mazingue, Lutz Patrick, MD, Cécile Vérité, MD, Christian Berthoux, MD, Claire Galambrun, MD, Frédéric Bernard, MD, Karima Yacouben, MD, Pierre Bordigoni, Pr, Christine Edan, MD, Yves Reguerre, MD, Gérard Couillaud, MD, Jean-Michel Cayuela, MD, François Guilhot, MD
Journal: Blood
Blood (2009) 114 (22): 863.
https://doi.org/10.1182/blood.V114.22.863.863
Published: 2009